중재적 종양학 시장 예측(-2030년) : 제품별, 적응증별, 시술 유형별, 최종사용자별, 지역별 세계 분석

According to Stratistics MRC, the Global Interventional Oncology Market is accounted for $2.4 billion in 2023 and is expected to reach $4.4 billion by 2030 growing at a CAGR of 8.8% during the forecast period. Within the area of interventional radiology, interventional oncology focuses on the use of minimally invasive methods for the detection and treatment of cancer. During these operations, imaging modalities including fluoroscopy, magnetic resonance imaging (MRI), computed tomography (CT), and ultrasound are used to guide the positioning of tools and provide targeted therapies directly to malignancies.

According to the American Cancer Society, a man's lifetime risk of developing breast cancer is about 1 in 833. Hence, with the growing burden of breast cancer, interventional oncology procedures are expected to increase over the forecast period, which will drive growth in the market

Market Dynamics:

Driver:

Growing demand for minimally invasive therapeutics

Interventional oncology treatments are becoming more widely used as a result of patients' and healthcare professionals' growing demand for minimally invasive procedures. Compared to open operations, these methods provide quicker recovery periods, shorter hospital stays, and fewer problems. As a result, the treatment of some cancer types is increasingly moving toward interventional oncology techniques. The movement toward patient-centric care, in which patients look for therapies that provide shorter recovery periods, fewer side effects, and enhanced quality of life, is consistent with minimally invasive procedures which boost the market growth.

Restraint:

Lack of qualified laboratory personnel

The quality of care given might be jeopardized by a lack of skilled laboratory professionals. Professionals with the necessary skills are essential for carrying out these complex operations precisely and accurately, and a lack might impact the level of knowledge available to get the best results. Patients may have restricted access to specialist Interventional Oncology services in areas or healthcare settings where there is a shortage of skilled staff. Thus, the capacity of patients to get minimally invasive cancer therapies may be impacted by this gap in access.

Opportunity:

Increase in the government support and reimbursement policies

Better reimbursement guidelines and increased government assistance might propel the market for interventional oncology therapies forward. Better financial incentives and coverage are expected to encourage more healthcare providers to provide these therapies, increasing patient accessibility. Patients pursuing interventional cancer therapies may face less financial obstacles with improved reimbursement regulations. This may result in more patients having access to these treatments, guaranteeing that more people will have access to cutting-edge, minimally invasive cancer treatments.

Threat:

Stringent regulations for medical devices

Creating novel medical devices for interventional oncology may become quite expensive as a result of the considerable testing, paperwork, and compliance procedures needed to meet strict regulatory criteria. The number of businesses ready to invest in research and development for new technologies may be hampered by higher development expenses. Although the goal of these laws is to protect patients, they can also impede the introduction of novel devices and technologies into the market, which could postpone the development of interventional oncology therapies.

COVID-19 Impact

Fears of contracting the virus in medical settings caused some patients to postpone receiving cancer therapies, especially interventional procedures, or seeking medical assistance altogether. It's possible that this delay interfered with the timely start or continuation of essential cancer therapies. In order to reduce hospital stays or the risk of contracting the virus, oncologists and other healthcare professionals may have modified treatment strategies, preferring systemic medications or other forms of therapy over interventional procedures.

The ablation devices segment is expected to be the largest during the forecast period

Due to the fact that ablation devices provide less intrusive options for treating a variety of tumor types, the market for these devices is predicted to increase profitably. These devices destroy tumors by using heat, cold, or other energy sources instead of surgical excision. These ablation devices are used in palliative care, tumor reduction, and tumor ablation, among other interventional oncology therapies. Their advantages over traditional surgery, such as less invasiveness, faster recovery, and fewer complications, make them desirable options for some cancer patients and drive the market.

The osteosarcoma segment is expected to have the highest CAGR during the forecast period

The osteosarcoma segment is anticipated to witness the highest CAGR growth during the forecast period; surgery, chemotherapy, and sometimes radiation therapy are used in conjunction as the conventional treatment for osteosarcoma. Interventional oncology methods, however, could be useful in some situations or in addition to conventional cancer therapies. Palliative treatment may involve interventional therapies if the osteosarcoma has progressed or caused problems. To treat pain or control symptoms related to bone metastases, for example, interventional radiology procedures such as tumor ablation (radiofrequency or cryoablation) may be employed.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period owing to A considerable number of cancer cases that are reported in Asia Pacific, with some of the region's nations having high incidence rates. The incidence of cancer in the area is influenced by a number of variables, including changes in lifestyle, alterations in the environment, and heightened cancer screening programs. Moreover the precision, effectiveness, and safety in cancer therapies are improved by the use of cutting-edge interventional oncology technology, including imaging modalities like MRI, CT, and ultrasound, in conjunction with cutting-edge instruments and equipment drives the growth of the market.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period, owing to the region's well-established healthcare system, technology developments, and the rising desire for minimally invasive cancer therapies are the main drivers of the market. Furthermore the high incidence of cancer, the region's well-established healthcare system, technology developments, and the rising desire for minimally invasive cancer therapies are the main drivers of the market.

Key players in the market:

Some of the key players profiled in the Interventional Oncology Market include AngioDynamics Inc., Cook Medical, HealthTronics Inc, Boston Scientific Corporation, Medtronic PLC, Terumo Corporation, Becton, Dickinson and Company, Merit Medical Systems Inc, Profound Medical Corp, IceCure Medical, Siemens Healthineers, Teleflex Incorporated, Medtronic Plc., Alpinion Medical Systems Co., IMBiotechnologies, Interface Biomaterials BV, Monteris Medical, Baylis Medical, Mermaid Medicals and Trod Medical

Key Developments:

In November 2023, Boston Scientific Corporation announced the close of its acquisition of Relievant Medsystems Inc., a company that offers the only U.S. Food and Drug Administration-cleared Intracept® Intraosseous Nerve Ablation System, a therapy to treat vertebrogenic pain that is a form of chronic low back pain.

In September 2023, Medtronic plc announced CE (Conformite Europeenne) Mark approval for its new all-in-one, disposable Simplera™ continuous glucose monitor (CGM) featuring a simple, two-step insertion process.

In July 2023, Purdue, IU and Cook Medical partner for 3-pronged approach to improve pediatric care. The Crossroads Pediatric Device Consortium will focus on meeting unmet needs for pediatric patients by accelerating the development, approval and availability of innovative medical devices for children.

Products Covered:

• Ablation Devices
• Embolization Devices
• Support Devices

Indications Covered:

• Hepatocellular Carcinoma
• Osteosarcoma
• Renal Cancer
• Lung Cancer
• Neuroendocrine Tumor
• Glioblastoma Multiforme
• Splenomegaly
• Metastatic Colorectal Cancer
• Other Indications

Procedure Types Covered:

• Transcatheter Arterial Radioembolization
• Transcatheter Arterial Chemoembolization
• Thermal Tumor Ablation
• Non-Thermal Tumor Ablation
• Transcatheter Arterial Embolization
• Other Procedure Types

End Users Covered:

• Ambulatory Surgery Centers
• Research & Academic Institutes
• Hospitals
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 End User Analysis
• 3.8 Emerging Markets
• 3.9 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Interventional Oncology Market, By Product

• 5.1 Introduction
• 5.2 Ablation Devices
  • 5.2.1 Cryoablation Devices
  • 5.2.2 Microwave Ablation Devices
  • 5.2.3 Radiofrequency (RF) Ablation Devices
  • 5.2.4 Other Ablation Devices
• 5.3 Embolization Devices
  • 5.3.1 Non-Radio embolic Agents
    • 5.3.1.1 Microspheres
    • 5.3.1.2 Microparticles
    • 5.3.1.3 Coated Beads
    • 5.3.1.4 Drug Eluting Beads
  • 5.3.2 Radioembolic Agents
• 5.4 Support Devices
  • 5.4.1 Guidewires
  • 5.4.2 Microcatheters

6 Global Interventional Oncology Market, By Indication

• 6.1 Introduction
• 6.2 Hepatocellular Carcinoma
• 6.3 Osteosarcoma
• 6.4 Renal Cancer
• 6.5 Lung Cancer
• 6.6 Neuroendocrine Tumor
• 6.7 Glioblastoma Multiforme
• 6.8 Splenomegaly
• 6.9 Metastatic Colorectal Cancer
• 6.10 Other Indications

7 Global Interventional Oncology Market, By Procedure Type

• 7.1 Introduction
• 7.2 Transcatheter Arterial Radioembolization
• 7.3 Transcatheter Arterial Chemoembolization
• 7.4 Thermal Tumor Ablation
• 7.5 Non-Thermal Tumor Ablation
• 7.6 Transcatheter Arterial Embolization
• 7.7 Other Procedure Types

8 Global Interventional Oncology Market, By End User

• 8.1 Introduction
• 8.2 Ambulatory Surgery Centers
• 8.3 Research & Academic Institutes
• 8.4 Hospitals
• 8.5 Other End Users

9 Global Interventional Oncology Market, By Geography

• 9.1 Introduction
• 9.2 North America
  • 9.2.1 US
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 Italy
  • 9.3.4 France
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 New Zealand
  • 9.4.6 South Korea
  • 9.4.7 Rest of Asia Pacific
• 9.5 South America
  • 9.5.1 Argentina
  • 9.5.2 Brazil
  • 9.5.3 Chile
  • 9.5.4 Rest of South America
• 9.6 Middle East & Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 UAE
  • 9.6.3 Qatar
  • 9.6.4 South Africa
  • 9.6.5 Rest of Middle East & Africa

10 Key Developments

• 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 10.2 Acquisitions & Mergers
• 10.3 New Product Launch
• 10.4 Expansions
• 10.5 Other Key Strategies

11 Company Profiling

• 11.1 AngioDynamics Inc.
• 11.2 Cook Medical
• 11.3 HealthTronics Inc.
• 11.4 Boston Scientific Corporation
• 11.5 Medtronic PLC
• 11.6 Terumo Corporation
• 11.7 Becton, Dickinson and Company
• 11.8 Merit Medical Systems Inc.
• 11.9 Profound Medical Corp.
• 11.10 IceCure Medical
• 11.11 Siemens Healthineers
• 11.12 Teleflex Incorporated
• 11.13 Medtronic Plc.
• 11.14 Alpinion Medical Systems Co.
• 11.15 IMBiotechnologies
• 11.16 Interface Biomaterials BV
• 11.17 Monteris Medical
• 11.18 Baylis Medical
• 11.19 Mermaid Medicals
• 11.20 Trod Medical